NASDAQ:NRBO NeuroBo Pharmaceuticals (NRBO) Stock Price, News & Analysis $1.58 +0.04 (+2.27%) As of 04/1/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NeuroBo Pharmaceuticals Stock (NASDAQ:NRBO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NRBO alerts:Sign Up Key Stats Today's Range$1.52▼$1.6550-Day Range$1.46▼$1.9852-Week Range$2.08▼$5.30Volume14,334 shsAverage Volume46,219 shsMarket Capitalization$13.57 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewNeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.Read More… Remove Ads NeuroBo Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreNRBO MarketRank™: NeuroBo Pharmaceuticals scored higher than 25% of companies evaluated by MarketBeat, and ranked 849th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNeuroBo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeuroBo Pharmaceuticals has received no research coverage in the past 90 days.Read more about NeuroBo Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NeuroBo Pharmaceuticals are expected to grow in the coming year, from ($3.91) to ($1.33) per share.Price to Book Value per Share RatioNeuroBo Pharmaceuticals has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about NeuroBo Pharmaceuticals' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NRBO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuroBo Pharmaceuticals does not currently pay a dividend.Dividend GrowthNeuroBo Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for NRBO. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows2 people have added NeuroBo Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NeuroBo Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.05% of the stock of NeuroBo Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 1.37% of the stock of NeuroBo Pharmaceuticals is held by institutions.Read more about NeuroBo Pharmaceuticals' insider trading history. Receive NRBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NRBO Stock News HeadlinesNeuroBo Pharmaceuticals (NRBO) Projected to Post Quarterly Earnings on ThursdayMarch 25, 2025 | americanbankingnews.comMTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…December 4, 2024 | msn.comTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.April 2, 2025 | Priority Gold (Ad)NeuroBo Pharmaceuticals Rebrands as MetaVia: Strategic Positioning and Growth Potential Highlighted in Buy Rating by Jason McCarthyNovember 21, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Rebrands Amidst Strategic ChangesNovember 19, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals announces relignment, change nameNovember 19, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic DiseasesNovember 18, 2024 | prnewswire.comNRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024November 13, 2024 | msn.comSee More Headlines NRBO Stock Analysis - Frequently Asked Questions How have NRBO shares performed this year? NeuroBo Pharmaceuticals' stock was trading at $2.03 at the beginning of 2025. Since then, NRBO stock has decreased by 22.4% and is now trading at $1.5750. View the best growth stocks for 2025 here. How were NeuroBo Pharmaceuticals' earnings last quarter? NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) released its earnings results on Thursday, November, 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.27. When did NeuroBo Pharmaceuticals' stock split? NeuroBo Pharmaceuticals shares reverse split on the morning of Thursday, December 21st 2023. The 1-8 reverse split was announced on Thursday, December 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of NeuroBo Pharmaceuticals? Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeuroBo Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroBo Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD), General Electric (GE) and Adobe (ADBE). Company Calendar Last Earnings11/07/2024Today4/02/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBanking Current SymbolNASDAQ:NRBO CIK1638287 Webwww.neurobopharma.com Phone(857) 702-9600Fax734-293-0444Employees10Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+534.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-189.12% Return on Assets-122.31% Debt Debt-to-Equity RatioN/A Current Ratio2.41 Quick Ratio2.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.50 per share Price / Book1.05Miscellaneous Outstanding Shares8,616,000Free Float8,526,000Market Cap$13.57 million OptionableNot Optionable Beta-0.26 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:NRBO) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.